Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

BACKGROUND: To improve antitumor effects against metastatic renal cell carcinoma (mRCC), use of molecular target-based drugs in sequential or combination therapy has been advocated. In combination therapy, interferon (IFN)-α amplified the effect of sorafenib in our murine model (J Urol 184:2549, 201...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Eto, Masatoshi, Kawano, Yoshiaki, Hirao, Yoshihiko, Mita, Koji, Arai, Yoichi, Tsukamoto, Taiji, Hashine, Katsuyoshi, Matsubara, Akio, Fujioka, Tomoaki, Kimura, Go, Shinohara, Nobuo, Tatsugami, Katsunori, Hinotsu, Shiro, Naito, Seiji
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4600287/
https://ncbi.nlm.nih.gov/pubmed/26452347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1675-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados